Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.

What symbol and exchange does Enlivex Ltd. - shares trade?

Enlivex Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

What is Enlivex Ltd. - stock price doing today?

As of October 26, 2026, ENLV stock price declined to $0.16 with 384,526 million shares trading.

What is Enlivex Ltd. -'s Beta?

ENLV has a beta of 0.55, meaning it tends to be less sensitive to market movements. ENLV has a correlation of 0.00 to the broad based SPY ETF.

How much is Enlivex Ltd. - worth?

ENLV has a market cap of $3.99 million. This is considered a Sub-Micro Cap stock.

What is the highest and lowest price Enlivex Ltd. - traded in the last 3 year period?

In the last 3 years, ENLV traded as high as $1,101.60 and as low as $.16.

Is Enlivex Ltd. - (ENLV) a good investment?

ENLV has underperformed the market in the last year with a price return of -99.9% while the SPY ETF gained +14.1%. ENLV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -99.8% and -96.0%, respectively, while the SPY returned +3.8% and -1.6%, respectively.

What are the support and resistance levels for Enlivex Ltd. - (ENLV)?

ENLV support price is $.16 and resistance is $.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.